Xintela’s main owner Flerie undertakes to exercise warrants TO3 of approximately SEK 28 million and provides a bridge loan of SEK 9 million

Xintela AB (publ) (“Xintela” or the “Company”) today announces that the Company’s largest shareholder Flerie Invest AB, which holds approximately 55.5 percent of the number of shares and votes in the Company, has committed to exercise warrants of series TO3 of approximately SEK 28 million during the exercise period beginning on November 25, 2024. Flerie’s undertaking means that all 93,630,256 warrants of series TO3 held by Flerie will be exercised to subscribe for shares in the Company.

Flerie has also provided a short-term bridge loan to Xintela of SEK 9 million, which is to be repaid no later than 16 December 2024. Furthermore, the maturity date for the other outstanding loans from Flerie to the Company – totalling approximately SEK 20.5 million – has been extended to 4 March 2025. In addition, it has been agreed that the maturity date of the loans may, at Xintela’s request, be extended to 30 April 2025. If the Company carries out a rights issue, Flerie has the right to subscribe for its preferential share with payment by set-off of outstanding loans.

The upcoming exercise period for the warrants of series TO3 is November 25 up to and including December 5, 2024. Further information will be published by the Company prior to the start of the exercise period.

This information is information that Xintela AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-01 08:30 CET.

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company’s cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela’s Certified Adviser is Carnegie Investment Bank AB (publ).

Links